Skip to main content
aap Implantate AG logo

aap Implantate AG — Investor Relations & Filings

Ticker · AAQ1 ISIN · DE000A3H2101 LEI · 39120001TRQTQ01LPP57 F Manufacturing
Open in API
Filings indexed 854 across all filing types
Latest filing 2019-08-14 Earnings Release
Country DE Germany
Listing F AAQ1

About aap Implantate AG

https://www.aap.de/

aap Implantate AG is a medical technology company that operates as a pure player in the field of traumatology. The company develops, manufactures, and markets implants for the treatment of bone fractures. Its core product is the LOQTEQ® system, a comprehensive portfolio of anatomical plates and screws featuring a patented technology that combines fracture compression with angle-stable locking. This titanium-based system is designed to cover a broad spectrum of indications in upper and lower extremity trauma surgery. In addition to its established product line, aap is developing next-generation platform technologies, including antibacterial silver-coated implants to reduce infection risk and resorbable magnesium implants intended to eliminate the need for secondary removal surgeries.

Recent filings

Filing Released Lang Actions
aap: Q2/2019 sales and EBITDA in line with guidance; double-digit sales growth in H1/2019
Earnings Release Classification · 100% confidence The document is dated August 14, 2019, and explicitly mentions 'Q2/2019 sales and EBITDA' and 'H1/2019' results. It contains detailed financial tables for the second quarter and the first half of the year, along with management commentary and an outlook. The key phrase in the metadata/header is 'Key word(s): Half Year Results'. This content structure—a summary of financial performance for a period shorter than a full year, including key metrics and management discussion—is characteristic of an Interim/Quarterly Report. It is comprehensive enough to be classified as 'IR' rather than just an 'ER' (Earnings Release) which is usually just highlights, and it is not the full annual report ('10-K'). The document also notes that the company will no longer publish a consolidated quarterly statement for Q3 due to a change in listing, reinforcing that this document serves the quarterly reporting function. H1 2019
2019-08-14 English
Datum:14.08.2019
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Halbjahresfinanzbericht 2019' (Half-Year Financial Report 2019) for 'aap Implantate AG'. It contains comprehensive financial statements, including balance sheets, income statements, cash flow data, and management commentary (Vorwort des Vorstandes) for the first half of the fiscal year. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. H1 2019
2019-08-14 German
aap Implantate AG adjusts outlook for financial year 2019
Earnings Release Classification · 100% confidence The document is an 'Ad-hoc' announcement dated August 13, 2019, explicitly stating that 'aap Implantate AG adjusts outlook for financial year 2019'. It details changes to sales and EBITDA forecasts for the full year, provides Q2 and H1 financial figures, and discusses strategic adjustments. This content—a material update on expected financial performance before the official annual or quarterly report—is characteristic of an Earnings Release (ER), which typically provides key highlights and guidance revisions. Although it contains some financial detail, its primary function is to announce the revised outlook, fitting the definition of an ER better than a comprehensive Interim Report (IR) or Annual Report (10-K). It is not a transcript (CT), a presentation (IP), or a formal regulatory filing like a 10-K. FY 2019
2019-08-13 English
aap receives BfArM approval for human clinical study and becomes global bellwether in antibacterial coating for trauma implants
Regulatory Filings Classification · 100% confidence The document is a news release dated August 8, 2019, disseminated via DGAP (a service often used for regulatory news). The content announces that aap Implantate AG has received approval from the BfArM (German Federal Institute for Drugs and Medical Devices) to start a human clinical study for its antibacterial coating technology. This is a specific, material corporate event announcement concerning regulatory progress and future product development, not a comprehensive financial report (like 10-K or IR), a transcript (CT), or a formal dividend/share change notice. It fits best under general Regulatory Filings (RNS) as it is a broad announcement of a significant corporate event/regulatory milestone that doesn't align perfectly with the other specific categories like ER, CAP, or LTR, although it does touch upon regulatory progress. Given the nature of the announcement (a specific regulatory approval milestone being made public), RNS is the most appropriate general regulatory announcement category.
2019-08-08 English
aap Implantate AG receives BfArM approval for human clinical study for its antibacterial silver coating technology
Legal Proceedings Report Classification · 99% confidence The document is dated August 8, 2019, and is labeled as an 'Ad-hoc' announcement. It discloses inside information according to Article 17 MAR (Market Abuse Regulation) and is transmitted by DGAP. The content announces a specific corporate event: receiving approval from BfArM for a human clinical study. This type of material, which is a significant, non-scheduled corporate update that is not a full financial report (like 10-K or IR), a management change (MANG), or a director's trade (DIRS), typically falls under general regulatory announcements or news releases. Since it is a specific, material, non-periodic disclosure mandated by EU regulation (MAR), it fits best under the general 'Regulatory Filings' category (RNS) as a fallback for significant, non-standard announcements, or potentially an Earnings Release (ER) if it were related to results, but it is not. Given the nature of an ad-hoc disclosure of a regulatory milestone, RNS is the most appropriate general regulatory category provided, as it is not a specific financial report, management change, or shareholder vote result.
2019-08-08 English
Report Publication Announcement 2019
Report Publication Announcement Classification · 100% confidence The document is very short (1603 characters) and explicitly states that it is a 'Preliminary announcement of the publication of financial reports'. It specifies the report being announced is the 'Financial report of the group (half-year/Q2)' and provides the future disclosure date (August 14, 2019) and links to where the report will be available. According to Rule #2 (The 'MENU VS MEAL' Rule), a short announcement stating that a report 'has been published' or will be published, without containing the full report content, should be classified as a Report Publication Announcement (RPA). The content perfectly matches the definition of RPA: 'Announcement regarding the timing, release, or publication of company reports'.
2019-08-06 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.